Hormone replacement as the first-line prevention for postmenopausal osteoporosis

References

• Jensen GF, Christiansen C, Transbol I. Fracture frequency and bone preservation in postmenopausal women treated with estrogen. Obstet. Gynecol.60, 493–496 (1982).
   PubMed Web of Science ®Google Scholar
• Lindsay R, Tohme JF. Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet. Gynecol.76, 290–295 (1990).
   PubMed Web of Science ®Google Scholar
• Oshima S, Onodera S, Amizuka N et al. Macrophage migration inhibitory factor-deficient mice are resistant to ovariectomy-induced bone loss. FEBS Lett.20(580), 1251–1256 (2006).
   Google Scholar
• Blair HC, Zaidi M. Osteoclastic differentiation and function regulated by old and new pathways. Rev. Endocr. Metab. Disord.7, 23–32 (2006).
   PubMed Web of Science ®Google Scholar
• Reifenstein EC, Albright F. The metabolic effects of steroid hormones in osteoporosis. J. Clin. Invest.26, 24–56 (1947).
   PubMed Web of Science ®Google Scholar
• Wallach S, Henneman PH. Prolonged estrogen therapy in postmenopausal women. JAMA171, 1637–1642 (1959).
   Web of Science ®Google Scholar
• Meema S, Bunker ML, Meema HE. Preventive effect of estrogen on postmenopausal bone loss. Arch. Intern. Med.135, 1436–1440 (1975).
   PubMedGoogle Scholar
• Lindsay R, Hart DM, Aitken JM, MacDonald EB, Anderson JB, Clarke AC. Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet1, 1038–1041 (1976).
   PubMed Web of Science ®Google Scholar
• Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement therapy I: a 10-year prospective study in the relationship to osteoporosis. Obstet. Gynecol.53, 277–281 (1979).
   PubMed Web of Science ®Google Scholar
• Christiansen C, Christensen MS, Transbol I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet1, 59–61 (1981).
   PubMed Web of Science ®Google Scholar
• Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann. Intern. Med.122, 9–16 (1995).
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA288, 321–333 (2002).
   PubMed Web of Science ®Google Scholar
• Farquhar CM, Marjoribanks J, Lethaby A, Lamberts Q, Suckling JA; Cochrane HT Study Group. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst. Rev.3, CD004143 (2005).
   Google Scholar
• Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA287, 2668–2676 (2002).
   PubMed Web of Science ®Google Scholar
• Genant HK, Lucas J, Weiss S et al. Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group. Arch. Intern. Med.157, 2609–2615 (1997).
   PubMed Web of Science ®Google Scholar
• Greenwald MW, Gluck OS, Lang E, Rakov V. Oral hormone therapy with 17β-estradiol and 17β-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects. Menopause12, 741–748 (2005).
   PubMed Web of Science ®Google Scholar
• Doren M, Nilsson JA, Johnell O. Effects of specific post-menopausal hormone therapies on bone mineral density in post-menopausal women: a meta-analysis. Hum. Reprod.18, 1737–1746 (2003).
   PubMed Web of Science ®Google Scholar
• Bagger YZ, Tankó LB, Alexandersen P et al. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone34, 728–735 (2004).
   PubMed Web of Science ®Google Scholar
• Briot K, Trémollières F, Thomas T, Roux C; Comité scientifique du GRIO. How long should patients take medications for postmenopausal osteoporosis? Joint Bone Spine74, 24–31 (2007).
   PubMed Web of Science ®Google Scholar
• Hickey M, Davis SR, Sturdee DW. Treatment of menopausal symptoms: what shall we do now? Lancet366, 409–421 (2005).
   PubMed Web of Science ®Google Scholar
• Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet362, 419–427 (2003).
   PubMed Web of Science ®Google Scholar
• Whitehead M, Farmer R. The million women study: a critique. Endocrine24, 187–193 (2004).
   PubMed Web of Science ®Google Scholar
• Shapiro S. The Million Women Study: potential biases do not allow uncritical acceptance of the data. Climacteric7, 3–7 (2004).
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR et al. Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA291, 1701–1712 (2004).
   PubMed Web of Science ®Google Scholar
• Anderson GL, Chlebowski RT, Rossouw JE et al. Prior hormone therapy and breast cancer risk in the Women’s Health Initiative randomized trial of estrogen plus progestin. Maturitas55, 103–115 (2006).
   PubMed Web of Science ®Google Scholar
• Bagger YZ, Tank LB, Alexandersen P, Riis BJ, Christiansen C. Overweight protects against osteoporotic fractures, but increases risk for estrogen-related cancer: The PERF Study. J. Bone Miner. Res.18(Suppl. 1), 174 (2003).
   Google Scholar
• Persson I, Adami HO, Johansson E, Lindberg B, Manell P, Westerholm B. Cohort study of oestrogen treatment and the risk of endometrial cancer: evaluation of method and its applicability. Eur. J. Clin. Pharmacol.25, 625–632 (1983).
   PubMed Web of Science ®Google Scholar
• Richman S, Edusa V, Fadiel A, Naftolin F. Low-dose estrogen therapy for prevention of osteoporosis: working our way back to monotherapy. Menopause13, 148–155 (2006).
   PubMed Web of Science ®Google Scholar
• Hopkins ML, Fung MF, Le T, Shorr R. Ovarian cancer patients and hormone replacement therapy: a systematic review. Gynecol. Oncol.92, 827–832 (2004).
   PubMed Web of Science ®Google Scholar
• Beral V, Million Women Study Collaborators, Bull D, Green J, Reeves G. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet369, 1703–1710 (2007).
   PubMed Web of Science ®Google Scholar
• Auranen A, Hietanen S, Salmi T, Grenman S. Hormonal treatments and epithelial ovarian cancer risk. Int. J. Gynecol. Cancer15, 692–700 (2005).
   PubMed Web of Science ®Google Scholar
• Bagger YZ, Tanko LB, Alexandersen P, Qin G, Christiansen C; PERF Study Group. Early postmenopausal hormone therapy may prevent cognitive impairment later in life. Menopause12, 12–17 (2005).
   PubMed Web of Science ®Google Scholar
• Genazzani AR, Pluchino N, Luisi S, Luisi M. Estrogen, cognition and female ageing. Hum. Reprod. Update13, 175–187 (2007).
   PubMed Web of Science ®Google Scholar
• Thakur MK, Sharma PK. Aging of brain: role of estrogen. Neurochem. Res.31, 1389–1398 (2006).
   PubMed Web of Science ®Google Scholar
• Simpkins JW, Singh M, Bishop J. The potential role for estrogen replacement therapy in the treatment of the cognitive decline and neurodegeneration associated with Alzheimer’s disease. Neurobiol. Aging15 (Suppl. 2), S195–S197 (1994).
   PubMedGoogle Scholar
• Xu H, Wang R, Zhang YW, Zhang X. Estrogen, β-amyloid metabolism/trafficking, and Alzheimer’s disease. Ann. NY Acad. Sci.1089, 324–342 (2006).
   PubMed Web of Science ®Google Scholar
• Shumaker SA, Legault C, Kuller L et al. Women’s Health Initiative Memory Study. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative Memory Study. JAMA291, 2947–2958 (2004).
   PubMed Web of Science ®Google Scholar
• Clarkson TB. The new conundrum: do estrogens have any cardiovascular benefits? Int. J. Fertil. Womens Med.47, 61–68 (2002).
   PubMedGoogle Scholar
• Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N. Engl. J. Med.313, 1044–1049 (1985).
   PubMed Web of Science ®Google Scholar
• Ostergaard S, Sondergaard BC, Hoegh-Andersen P et al. Effects of ovariectomy and estrogen therapy on type II collagen degradation and structural integrity of articular cartilage in rats: implications of the time of initiation. Arthritis Rheum.54, 2441–2451 (2006).
   PubMedGoogle Scholar
• Ham KD, Oegema TR, Loeser RF, Carlson CS. Effects of long-term estrogen replacement therapy on articular cartilage IGFBP-2, IGFBP-3, collagen and proteoglycan levels in ovariectomized cynomolgus monkeys. Osteoarthr. Cartil.12, 160–168 (2004).
   PubMed Web of Science ®Google Scholar
• Richette P, Dumontier MF, Tahiri K et al. Oestrogens inhibit interleukin 1β-mediated nitric oxide synthase expression in articular chondrocytes through nuclear factor-kappa B impairment. Ann. Rheum. Dis.66, 345–350 (2007).
   PubMedGoogle Scholar
• Richette P, Corvol M, Bardin T. Estrogens, cartilage, and osteoarthritis. Joint Bone Spine70, 257–262 (2003).
   PubMed Web of Science ®Google Scholar
• Riggs BL, Melton LJ 3rd, O’Fallon WM. Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Bone18(3 Suppl.), 197S–201S (1996).
   PubMed Web of Science ®Google Scholar
• Delmas PD, Bjarnason NH, Mitlak BH et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med.337, 1641–1647 (1997).
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Mosca L, Collins P et al. Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N. Engl. J. Med.355, 125–137 (2006).
   PubMed Web of Science ®Google Scholar
• Ellerington MC, Hillard TC, Whitcroft SI et al. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis. Calcif. Tissue Int.59, 6–11 (1996).
   PubMed Web of Science ®Google Scholar
• Hosking D, Chilvers CE, Christiansen C et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N. Engl. J. Med.338, 485–492 (1998).
   PubMed Web of Science ®Google Scholar
• Black DM, Thompson DE, Bauer DC et al. Fracture Intervention Trial. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J. Clin. Endocrinol. Metab.85, 4118–4124 (2000).
   PubMed Web of Science ®Google Scholar
• McClung M, Clemmesen B, Daifotis A et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann. Intern. Med.128, 253–261 (1998).
   PubMed Web of Science ®Google Scholar
• Reginster JY, Adami S, Lakatos P et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann. Rheum. Dis.65, 654–661 (2006).
   PubMed Web of Science ®Google Scholar
• Cranney A, Adachi J, Guyatt G, Papaioannou A et al. WITHDRAWN: risedronate for the prevention and treatment of postmenopausal osteoporosis. Cochrane Database Syst. Rev.3, CD004523 (2007).
   Google Scholar
• Alexandersen P, Riis BJ, Stakkestad JA, Delmas PD, Christiansen C. Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy. J. Clin. Endocrinol. Metab.86, 755–760 (2001).
   PubMed Web of Science ®Google Scholar
• Suda T, Udagawa N, Takahashi N. Cells of bone: osteoclast generation. In: Principles of Bone Biology. Bilezikian JP, Raisz LG, Rodan GA (Eds). New York: Academic Press, NY, USA 87–102 (1996).
   Google Scholar
• Talmage RV, Elliott JR. Removal of calcium from bone as influenced by the parathyroids. Endocrinology62, 717–722 (1958).
   PubMed Web of Science ®Google Scholar
• Greenspan SL, Bone HG, Ettinger MP et al. Treatment of osteoporosis with parathyroid hormone study group. Effect of recombinant human parathyroid hormone (1–84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann. Intern. Med.146, 326–339 (2007).
   PubMed Web of Science ®Google Scholar
• Lindsay R, Nieves J, Formica C et al. Randomized controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet350, 550–555 (1997).
   PubMed Web of Science ®Google Scholar
• Cosman F, Nieves J, Woelfert L et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J. Bone Miner. Res.16, 925–931 (2001).
   PubMed Web of Science ®Google Scholar
• Meunier PJ, Roux C, Seeman E et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med.350, 459–468 (2004).
   PubMed Web of Science ®Google Scholar
• Reginster JY, Seeman E, De Vernejoul MC et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J. Clin. Endocrinol. Metab.90, 2816–2822 (2005).
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA280, 605–613 (1998).
   PubMed Web of Science ®Google Scholar
• Manson JE, Hsia J, Johnson KC et al. Women’s Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N. Engl. J. Med.349, 523–534 (2003).
   PubMed Web of Science ®Google Scholar
• Notelovitz M. The clinical practice impact of the Women’s Health Initiative: political vs biologic correctness. Maturitas44, 3–9 (2003).
   PubMed Web of Science ®Google Scholar
• Mikkola TS, Clarkson TB, Notelovitz M. Postmenopausal hormone therapy before and after the women's health initiative study: what consequences? Ann. Med.36, 402–413 (2004).
   PubMed Web of Science ®Google Scholar
• Clarkson TB, Appt SE. MPA and postmenopausal coronary artery atherosclerosis revisited. Steroids68, 941–951 (2003).
   PubMed Web of Science ®Google Scholar
• Koh KK, Sakuma I. Should progestins be blamed for the failure of hormone replacement therapy to reduce cardiovascular events in randomized controlled trials? Arterioscler. Thromb. Vasc. Biol.24, 1171–1179 (2004).
   PubMed Web of Science ®Google Scholar
• Haarbo J, Leth-Espensen P, Stender S, Christiansen C. Estrogen monotherapy and combined estrogen–progestogen replacement therapy attenuate aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits. J. Clin. Invest.87, 1274–1279 (1991).
   PubMed Web of Science ®Google Scholar
• Alexandersen P, Haarbo J, Sandholdt I, Shalmi M, Lawaetz H, Christiansen C. Norethindrone acetate enhances the antiatherogenic effect of 17β-estradiol: a secondary prevention study of aortic atherosclerosis in ovariectomized cholesterol-fed rabbits. Arterioscler. Thromb. Vasc. Biol.18, 902–907 (1998).
   PubMed Web of Science ®Google Scholar
• Falkeborn M, Persson I, Adami HO et al. The risk of acute myocardial infarction after oestrogen and oestrogen–progestogen replacement. Br. J. Obstet. Gynaecol.99, 821–828 (1992).
   PubMedGoogle Scholar
• Grodstein F, Stampfer MJ, Falkeborn M, Naessen T, Persson I. Postmenopausal hormone therapy and risk of cardiovascular disease and hip fracture in a cohort of Swedish women. Epidemiology10, 476–480 (1999).
   PubMed Web of Science ®Google Scholar
• Alexandersen P, Tanko LB, Bagger YZ, Qin G, Christiansen C. The long-term impact of 2–3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women. Climacteric9, 108–118 (2006).
   PubMed Web of Science ®Google Scholar
• Mikkola TS, Clarkson TB. Coronary heart disease and postmenopausal hormone therapy: conundrum explained by timing? J. Womens Health (Larchmt).15, 51–53 (2006).
   PubMed Web of Science ®Google Scholar
• Holm P, Andersen HL, Andersen MR, Erhardtsen E, Stender S. The direct antiatherogenic effect of estrogen is present, absent, or reversed, depending on the state of the arterial endothelium. A time course study in cholesterol-clamped rabbits. Circulation100, 1727–1733 (1999).
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Prentice RL, Manson JE et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA297, 1465–1477 (2007).
   PubMed Web of Science ®Google Scholar
• Manson JE, Allison MA, Rossouw JE et al. WHI and WHI–CACS Investigators. Estrogen therapy and coronary-artery calcification. N. Engl. J. Med.356, 2591–2602 (2007).
   PubMed Web of Science ®Google Scholar
• Koh KK. Effects of estrogen on the vascular wall: vasomotor function and inflammation. Cardiovasc. Res.55, 714–726 (2002).
   PubMed Web of Science ®Google Scholar
• Libby P. Vascular biology of atherosclerosis: overview and state of the art. Am. J. Cardiol.91, 3A–6A (2003).
   PubMed Web of Science ®Google Scholar
• Pradhan AD, Manson JE, Rossouw JE et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women’s Health Initiative observational study. JAMA288, 980–987 (2002).
   PubMed Web of Science ®Google Scholar
• Usher C, Teeling M, Bennett K, Feely J. Effect of clinical trial publicity on HRT prescribing in Ireland. Eur. J. Clin. Pharmacol.62, 307–310 (2006).
   PubMed Web of Science ®Google Scholar
• Tanko LB, Bagger YZ, Alexandersen P, Larsen PJ, Christiansen C. Central and peripheral fat mass have contrasting effect on the progression of aortic calcification in postmenopausal women. Eur. Heart J.24, 1531–1537 (2003).
   PubMed Web of Science ®Google Scholar
• Howard BV, Hsia J, Ouyang P et al. Postmenopausal hormone therapy is associated with atherosclerosis progression in women with abnormal glucose tolerance. Circulation110, 201–206 (2004).
   PubMed Web of Science ®Google Scholar
• Pines A, Sturdee DW, Birkhäuser MH, Schneider HP, Gambacciani M, Panay N. Board of the International Menopause Society, IMS updated recommendations on postmenopausal hormone therapy. Climacteric10, 181–194 (2007).
   PubMed Web of Science ®Google Scholar
• Tanko LB, Bagger YZ, Qin G, Alexandersen P, Larsen PJ, Christiansen C. Enlarged waist combined with elevated triglycerides is a strong predictor of accelerated atherogenesis and related cardiovascular mortality in postmenopausal women. Circulation111, 1883–1890 (2005).
   PubMed Web of Science ®Google Scholar
• Rowan JP, Simon JA, Speroff L, Ellman H. Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 µg) in women with postmenopausal symptoms: updated analysis of three randomized, controlled trials. Clin. Ther.28, 921–932 (2006).
   PubMed Web of Science ®Google Scholar